Raquel de Paz

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · The Lancet Oncology · 2010 · 459 citations · Full text

Medicine, Hematology, Pharmacology +17

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

Juan José Lahuerta, Bruno Paiva, María‐Belén Vídriales et al. · Journal of Clinical Oncology · 2017 · 318 citations · Full text

Medicine, Hematology, Oncology +17

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

Bruno Paiva, Norma C. Gutiérrez, Laura Rosiñol et al. · Blood · 2011 · 304 citations · Full text

Medicine, Hematology, Oncology +17

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

Bruno Paiva, Joaquín Martínez‐López, María‐Belén Vídriales et al. · Journal of Clinical Oncology · 2011 · 233 citations · Full text

Medicine, Hematology, Oncology +13

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase

François-Xavier Mahon, Carla Boquimpani, Dong‐Wook Kim et al. · Annals of Internal Medicine · 2018 · 132 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11